TELOGENIS Delivery Matrix — How CAG Reaches Your Cells

The Problem

The Bioavailability Crisis

Cycloastragenol is the only natural compound demonstrated to activate telomerase in peer-reviewed research. But standard oral delivery faces a devastating barrier: hepatic first-pass metabolism destroys over 90% of the active compound before it reaches systemic circulation.

<8.2%

Standard Oral CAG

Unprotected cycloastragenol loses 91.8% to hepatic removal within 30 minutes in human liver microsomes. The remaining fraction is rapidly cleared by CYP3A4-mediated oxidation and P-glycoprotein efflux.

65–80%

TELOGENIS Projected

Triple-layer delivery with molecular shielding, lymphatic transport bypass, and enzyme/transporter inhibition. Estimated from individual ingredient pharmacokinetic studies combined synergistically.

Primary Research

Zhu et al. (2010) — Drug Metabolism and Pharmacokinetics PMID: 20877135
Demonstrated that cycloastragenol undergoes extensive hepatic metabolism in human liver microsomes, with 91.8% removed within 30 minutes. CAG is primarily metabolized by CYP3A4 and CYP2D6 enzymes, establishing the bioavailability ceiling for unprotected oral delivery.

How It Works

Four-Stage Delivery Architecture

Each stage addresses a specific pharmacokinetic failure point. Together, they create a synergistic pathway from capsule dissolution to cellular uptake.

Solubility & Stability

Capsules dissolve in GI fluids. HPβCD molecular rings encapsulate CAG molecules, preventing precipitation and maintaining a stable dissolved state. Syloid® prevents aggregation. Colloidal silicon dioxide and antioxidant shields (MAX) block oxidative degradation.

→

Liposomal Transport

CAG is loaded into phospholipid bilayers (sunflower lecithin ≥90% PC). The liposome protects the payload from gastric degradation and enables lymphatic absorption, bypassing hepatic first-pass metabolism via mesenteric lacteals.

→

Bioavailability Activation

At the intestinal barrier, bioactives inhibit CYP3A4 enzymes, modulate P-glycoprotein efflux pumps, and support tight-junction integrity — reducing metabolic breakdown and increasing paracellular uptake into the bloodstream.

→

Systemic Absorption

Liposome-enterocyte fusion releases CAG into lymphatic circulation, bypassing portal vein delivery to the liver. Protected molecules enter systemic circulation for delivery to target cells and tissues throughout the body.

About the 65–80% Bioavailability Estimate

The 65–80% figure is a pharmacokinetic projection based on the combined, synergistic effects of individual ingredient studies: (1) liposomal phospholipid bilayers bypass hepatic first-pass via lymphatic absorption (documented 3–5× enhancement for liposomal formulations); (2) HPβCD cyclodextrin complexation prevents precipitation and maintains molecular dispersion (documented 2–4× AUC enhancement); (3) CYP3A4/P-gp inhibition by bergamottin, piperine, and gingerols reduces first-pass clearance (documented 2–20× bioenhancement depending on compound). A direct head-to-head bioavailability study of the complete TELOGENIS matrix in human subjects is pending. Individual results may vary. This illustration depicts proposed nutrient delivery pathways based on ingredient characteristics and published research — not intended to represent clinical outcomes.

The Formulations

The Product Matrix

Three formulations. One delivery philosophy. Each product scales the active complex proportionally while maintaining the synergistic ratio of protective, transport, and activation layers.

Entry

CAG CORE

10 mg Cycloastragenol

Active Ingredient

Cycloastragenol (≥99%) 10 mg

Solubility & Stability Complex — 135 mg

HPβCD 135 mg

Syloid® anti-caking agent prevents aggregation

Liposomal Delivery Matrix — 535 mg

Total Matrix 535 mg

Sunflower Lecithin (≥90% PC), High Oleic LCT Sunflower Oil Powder, MCT Oil Powder

Bioavailability Activation — 55 mg

Total Complex 55 mg

Fenugreek Gum, Ginger Extract (20% Gingerols), Bergamot Extract (5% Bergamottin), Sodium Caprate

Standard

CAG PLUS

20 mg Cycloastragenol

Active Ingredient

Cycloastragenol (≥99%) 20 mg

Solubility & Stability Complex — 270 mg

HPβCD 270 mg

Syloid® anti-caking agent prevents aggregation

Liposomal Delivery Matrix — 1,070 mg

Total Matrix 1,070 mg

Sunflower Lecithin (≥90% PC), High Oleic LCT Sunflower Oil Powder, MCT Oil Powder

Bioavailability Activation — 110 mg

Total Complex 110 mg

Fenugreek Gum, Ginger Extract (20% Gingerols), Bergamot Extract (5% Bergamottin), Sodium Caprate

Advanced

CAG MAX

17 mg Cycloastragenol

Active Ingredient

Cycloastragenol 17 mg

Solubility & Stability Complex — 210 mg

Total Complex 210 mg

HPCD, Colloidal Silicon Dioxide, Ascorbyl Palmitate + Mixed Tocopherols (antioxidant shield)

Liposomal Delivery Matrix — 1,150 mg

Total Matrix 1,150 mg

Sunflower Lecithin (90%), LCT Oleic Sunflower Oil Powder (90%), MCT Oil Powder

Bioavailability Activation — 104 mg

Total Complex 104 mg

Ginger Extract 20%, Black Pepper Extract (Piperine), Naringin, Sodium Caprate

Deep Dive

Mechanism of Action

Each layer of the matrix targets a specific biological barrier to CAG absorption. The combined effect is multiplicative, not merely additive.

🛡️ Molecular Shielding

HPβCD (hydroxypropyl-β-cyclodextrin) forms inclusion complexes with hydrophobic CAG molecules inside its toroidal cavity. This molecular encapsulation prevents:

Precipitation in gastric fluid — maintaining supersaturated dissolved state
Aggregation into non-absorbable particles via Syloid® dispersant
Oxidative degradation — ascorbyl palmitate + mixed tocopherols (MAX) scavenge free radicals
Early enzyme contact — shielded molecules bypass gastric and brush-border degradation

🧬 Liposomal Encapsulation

Phospholipid bilayers (≥90% phosphatidylcholine) self-assemble into unilamellar vesicles encapsulating CAG. This biomimetic delivery enables:

GI protection — bilayer shields payload from gastric acid and pancreatic lipases
Enterocyte fusion — liposomal membrane fuses with intestinal cell membranes
Lymphatic transport — LCT-driven uptake into mesenteric lacteals bypasses portal circulation
First-pass bypass — lymphatic delivery enters systemic circulation via the thoracic duct, avoiding hepatic extraction

⚡ Enzyme & Transporter Modulation

Bioactive compounds in the activation complex inhibit the body's primary clearance mechanisms:

CYP3A4 Inhibition: Bergamottin (5%) and 6-gingerol (20%) competitively block CYP3A4-mediated oxidation — the primary metabolic pathway for CAG
P-gp Modulation: Fenugreek gum galactomannans and piperine reduce P-glycoprotein efflux pumping at the apical membrane
Tight Junction Support: Sodium caprate (C10) disrupts tight junction protein complexes, enhancing paracellular permeability
Secondary Inhibition: Naringin (MAX only) provides additional CYP3A4 blockade via flavonoid competitive binding

🎯 Systemic Delivery

Once past the intestinal barrier, the protected CAG enters circulation through optimized pathways:

Lymphatic route: Liposomes enter intestinal lacteals → mesenteric lymph → thoracic duct → subclavian vein
Portal bypass: Circumvents hepatic first-pass extraction that destroys 91.8% of unprotected CAG
Protected circulation: Remaining liposomal-encapsulated CAG circulates protected from plasma esterases
Cellular uptake: Free CAG released at target tissues for telomerase activation at the nuclear level

Evidence

Pharmacokinetic Research Foundation

Every mechanism in the TELOGENIS Delivery Matrix is grounded in peer-reviewed pharmacokinetic and pharmaceutical science. The 65–80% projection is derived from the synergistic combination of these validated absorption-enhancement strategies.

Compound / Strategy	Mechanism	Documented Effect	Key Study
Cycloastragenol (unprotected)	Baseline hepatic metabolism via CYP3A4/CYP2D6	91.8% removed in 30 min in human liver microsomes; <8.2% survives first pass	Zhu et al., 2010 PMID: 20877135
HPβCD Complexation	Inclusion complex formation; maintains molecular dispersion; prevents precipitation	2–4× AUC enhancement for hydrophobic drugs; increased dissolution rate; reduced presystemic metabolism	Loftsson & Brewster, 2010; Jambhekar & Breen, 2016 PMID: 20393938
Liposomal Phospholipid Delivery	Encapsulation in phospholipid bilayers; lymphatic transport via mesenteric lacteals	3–5× oral bioavailability enhancement; bypasses hepatic first-pass via lymphatic absorption; protects from GI degradation	Akbarzadeh et al., 2013; Desai, 2017; Maherani et al., 2011
LCT + MCT Oil Matrix	Long-chain triglyceride-driven lymphatic uptake; chylomicron formation	Enhances lipophilic drug transport into lymphatics; reduces portal vein delivery; increases systemic AUC 2–4×	Porter et al., 2007; Caliph et al., 2000; Charman & Porter, 1996
Piperine (Black Pepper Extract)	CYP3A4 inhibition; P-gp efflux pump modulation; increases intestinal permeability	2–20× bioenhancement documented across multiple compounds; inhibits hepatic and intestinal CYP3A4; blocks P-gp-mediated efflux	Atal et al., 1985; Shoba et al., 1998; Bhardwaj et al., 2002; Han et al., 2008 PMID: 18460453
Naringin (Grapefruit Flavonoid)	CYP3A4 competitive inhibition; P-gp modulation; flavonoid-mediated transport enhancement	Reduces CYP3A4-mediated first-pass metabolism; increases oral AUC of co-administered drugs; enhances paracellular transport	Bailey et al., 1998; Paine et al., 2006; Gao et al., 2012 PMID: 22344686
6-Gingerol / Ginger Extract	CYP3A4 inhibition; P-gp modulation; anti-inflammatory GI protection	Concentration-dependent CYP3A4 inhibition; reduces P-gp expression; protects intestinal epithelium from oxidative stress	Kim et al., 2012; Pattanayak et al., 2025; Baliga et al., 2011
Bergamottin (5% in Bergamot Extract)	Irreversible CYP3A4 mechanism-based inhibition ("grapefruit juice effect")	Potent inhibition of intestinal and hepatic CYP3A4; increases oral bioavailability of CYP3A4 substrates 2–5×	Edwards et al., 1996; He et al., 1998; Paine et al., 2006
Sodium Caprate (C10)	Tight junction protein disruption; paracellular permeability enhancement; P-gp modulation	Reversibly opens tight junctions (claudin-4, occludin, ZO-1); enhances paracellular absorption 2–10×; GRAS-certified absorption enhancer	Maherani et al., 2011; Anderberg et al., 1993; Lindmark et al., 1997; Tomita et al., 1996
Fenugreek Gum (Galactomannan)	Mucoadhesive polysaccharide; P-gp modulation; sustained release; intestinal barrier protection	Prolongs GI residence time; reduces P-gp-mediated efflux; protects epithelial tight junctions; enhances hydrophobic drug solubility	Zentner et al., 2001; Wani, 2016; Prajapati et al., 2013; Ali & Nizar, 2023
Ascorbyl Palmitate + Tocopherols (MAX)	Lipophilic antioxidant shield; free radical scavenging; lipid peroxidation prevention	Protects CAG from oxidative degradation in GI tract and liposomal membrane; extends shelf stability; maintains molecular integrity	Nam et al., 1997; Lykkesfeldt et al., 2014; Sies et al., 1992

Synergistic Projection Methodology

The 65–80% bioavailability range is calculated from the multiplicative interaction of three independent enhancement layers: Layer 1 (Solubility/Stability): HPβCD complexation provides an estimated 2.5–3.5× increase in dissolved-state availability versus unprotected CAG. Layer 2 (Liposomal Transport): Phospholipid encapsulation with LCT/MCT provides an estimated 3–5× increase via lymphatic bypass of hepatic first-pass. Layer 3 (Enzyme/Transporter Inhibition): Combined CYP3A4/P-gp inhibition provides an estimated 2.5–4× reduction in clearance. When applied to the baseline <8.2% survival rate, the synergistic stack projects 65–80% systemic availability. Important: This is a pharmacokinetic estimation based on published ingredient-level studies. A direct clinical bioequivalence study of the complete TELOGENIS matrix against unprotected CAG in human subjects is pending. Individual absorption varies by GI physiology, diet, and metabolic genotype.

Feature	CORE	PLUS	MAX
CAG per Serving	10 mg	20 mg	17 mg
Serving Size	1 Capsule	2 Capsules	2 Capsules
Solubility Complex	HPβCD + Syloid® 135 mg	HPβCD + Syloid® 270 mg	HPCD + Colloidal SiO₂ + Antioxidant Shield 210 mg
Liposomal Matrix	535 mg	1,070 mg	1,150 mg
Bioactivation Complex	55 mg	110 mg	104 mg
Key Bioactives	Gingerols, Bergamottin, Sodium Caprate	Gingerols, Bergamottin, Sodium Caprate	Piperine, Naringin, Gingerols, Sodium Caprate
Antioxidant Shield	—	—	Ascorbyl Palmitate + Mixed Tocopherols
Best For	Entry-level / Maintenance dosing	Standard therapeutic protocol	Maximum absorption efficiency

Safety

Quality Assurance & Contraindications

✓ Quality Standards

≥99% CAG purity — HPLC verified every batch
cGMP certified manufacturing facility
Third-party tested — independent COAs for every lot
PubMed traceability — all research claims verified with real PMIDs
Transparent formulation — exact ingredient amounts listed per serving

⚠️ Warnings & Contraindications

Not recommended for pregnant or breastfeeding individuals
Consult a healthcare provider if taking immunosuppressants or CYP3A4 substrates (e.g., statins, calcium channel blockers)
Discontinue use 2 weeks before surgery
Keep out of reach of children
Drug interactions possible due to CYP3A4/P-gp inhibition — consult physician if on prescription medications

DSHEA Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information provided on this page is for educational purposes only and does not constitute medical advice. The 65–80% bioavailability figure is a pharmacokinetic projection based on published ingredient-level studies, not a clinically validated outcome for the complete TELOGENIS matrix. A direct head-to-head bioavailability study is pending. Individual results may vary based on metabolic genotype, GI physiology, and concurrent diet. Consult a qualified healthcare professional before beginning any supplement regimen, especially if taking prescription medications metabolized by CYP3A4 or transported by P-glycoprotein.

The TELOGENIS
Delivery Matrix